Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase

DSpace Repository


Dateien:

URI: http://hdl.handle.net/10900/84181
http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-841815
http://dx.doi.org/10.15496/publikation-25571
Dokumentart: Dissertation
Date: 2018-09-17
Language: English
Faculty: 4 Medizinische Fakultät
Department: Medizin
Advisor: Weber, Alexander (Prof. Dr.)
Day of Oral Examination: 2018-07-31
DDC Classifikation: 500 - Natural sciences and mathematics
610 - Medicine and health
Keywords: Immunbiologie
Other Keywords: Verordnung
BTK
NLRP3 inflammasome
regulation
License: Publishing license including print on demand
Order a printed copy: Print-on-Demand
Show full item record

Abstract:

The Nod-like receptor, NLRP3, has been described as a key immune sensor of microbial, environmental and endogenous insults or stress. The multimeric NLRP3 inflammasome recruits the adaptor protein ASC to activate caspase-1, leading to the maturation of the pro-inflammatory cytokines Interleukin (IL)-1β and IL-18. The NLRP3 inflammasome has a fundamental role in host defense against microbial pathogens but its deregulation is also implicated in sterile inflammation and the pathogenesis of several inflammatory diseases including Muckle-Wells Syndrome (MWS) caused by inherited NLRP3 mutations. NLRP3 inflammasome activity is tightly controlled to maintain immune homeostasis and avoid detrimental effects. However, the regulatory mechanism of this complex and medically relevant process are poorly understood. In this study, we identified Bruton’s tyrosine kinase (BTK), a non-receptor protein tyrosine kinase of the TEC family of proteins, as a novel regulator of the NLRP3 inflammasome by an unbiased triple SILAC phospho-proteomics. Further results revealed that pharmacological (using the Food and Drug Administration (FDA)-approved inhibitor, ibrutinib) and genetic (in BTK-mutated patients and Btk-knockout mice) BTK ablation attenuated caspase-1 activation and IL-1β maturation in response to Nigericin and the Staphylococcus aureus toxin, LukAB. Additionally, BTK directly interacted with NLRP3 and ASC, and promoted ASC speck formation and caspase-1 cleavage. Consistently, ibrutinib inhibited IL-1β release from immune cells of MWS patients. More importantly, obtained results from immune cells of ibrutinib therapy treated cancer patients provide evidence that in vivo application of ibrutinib affects IL-1ß processing and release in response to Nigericin. Thus, our data suggest that BTK is a critical regulator of NLRP3 inflammasome activation and that NLRP3 inflammasome-associated inflammatory diseases could potentially be targeted via BTK.

This item appears in the following Collection(s)